BEAM
Price
$30.43
Change
-$2.71 (-8.18%)
Updated
Feb 21 closing price
Capitalization
2.52B
10 days until earnings call
PRME
Price
$2.96
Change
-$0.17 (-5.43%)
Updated
Feb 21 closing price
Capitalization
388.24M
12 days until earnings call
Ad is loading...

BEAM vs PRME

Header iconBEAM vs PRME Comparison
Open Charts BEAM vs PRMEBanner chart's image
Beam Therapeutics
Price$30.43
Change-$2.71 (-8.18%)
Volume$1.88M
Capitalization2.52B
Prime Medicine
Price$2.96
Change-$0.17 (-5.43%)
Volume$805.56K
Capitalization388.24M
BEAM vs PRME Comparison Chart
Loading...
BEAM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PRME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BEAM vs. PRME commentary
Feb 22, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BEAM is a Hold and PRME is a Hold.

Ad is loading...
COMPARISON
Comparison
Feb 22, 2025
Stock price -- (BEAM: $33.49 vs. PRME: $2.99)
Brand notoriety: BEAM and PRME are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BEAM: 168% vs. PRME: 155%
Market capitalization -- BEAM: $2.52B vs. PRME: $388.24M
BEAM [@Biotechnology] is valued at $2.52B. PRME’s [@Biotechnology] market capitalization is $388.24M. The market cap for tickers in the [@Biotechnology] industry ranges from $393.7B to $0. The average market capitalization across the [@Biotechnology] industry is $2.43B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BEAM’s FA Score shows that 0 FA rating(s) are green whilePRME’s FA Score has 0 green FA rating(s).

  • BEAM’s FA Score: 0 green, 5 red.
  • PRME’s FA Score: 0 green, 5 red.
According to our system of comparison, BEAM is a better buy in the long-term than PRME.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BEAM’s TA Score shows that 6 TA indicator(s) are bullish while PRME’s TA Score has 5 bullish TA indicator(s).

  • BEAM’s TA Score: 6 bullish, 4 bearish.
  • PRME’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, both BEAM and PRME are a good buy in the short-term.

Price Growth

BEAM (@Biotechnology) experienced а +24.73% price change this week, while PRME (@Biotechnology) price change was +31.14% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.27%. For the same industry, the average monthly price growth was +3.99%, and the average quarterly price growth was +2.35%.

Reported Earning Dates

BEAM is expected to report earnings on May 13, 2025.

PRME is expected to report earnings on May 09, 2025.

Industries' Descriptions

@Biotechnology (+4.27% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BEAM($2.52B) has a higher market cap than PRME($388M). BEAM YTD gains are higher at: 35.040 vs. PRME (2.397). BEAM has higher annual earnings (EBITDA): -160.83M vs. PRME (-207.13M). BEAM has more cash in the bank: 926M vs. PRME (176M). PRME has less debt than BEAM: PRME (41.2M) vs BEAM (162M). BEAM has higher revenues than PRME: BEAM (350M) vs PRME (800K).
BEAMPRMEBEAM / PRME
Capitalization2.52B388M649%
EBITDA-160.83M-207.13M78%
Gain YTD35.0402.3971,462%
P/E RatioN/AN/A-
Revenue350M800K43,750%
Total Cash926M176M526%
Total Debt162M41.2M393%
FUNDAMENTALS RATINGS
PRME: Fundamental Ratings
PRME
OUTLOOK RATING
1..100
70
VALUATION
overvalued / fair valued / undervalued
1..100
71
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
64
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
BEAMPRME
RSI
ODDS (%)
Bearish Trend 5 days ago
81%
Bullish Trend 5 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 5 days ago
90%
Bearish Trend 5 days ago
78%
Momentum
ODDS (%)
Bullish Trend 5 days ago
84%
Bullish Trend 5 days ago
83%
MACD
ODDS (%)
Bullish Trend 5 days ago
81%
Bullish Trend 5 days ago
86%
TrendWeek
ODDS (%)
Bullish Trend 5 days ago
82%
Bullish Trend 5 days ago
81%
TrendMonth
ODDS (%)
Bullish Trend 5 days ago
82%
Bullish Trend 5 days ago
73%
Advances
ODDS (%)
Bullish Trend 5 days ago
80%
Bullish Trend 5 days ago
78%
Declines
ODDS (%)
Bearish Trend 16 days ago
85%
Bearish Trend 12 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 5 days ago
90%
N/A
Aroon
ODDS (%)
Bullish Trend 5 days ago
80%
Bearish Trend 5 days ago
90%
View a ticker or compare two or three
Ad is loading...
BEAM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PRME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
SPY611.491.79
+0.29%
SPDR® S&P 500® ETF Trust
AAPL244.47-0.13
-0.05%
Apple
GME26.97-0.03
-0.11%
GameStop Corp
BTC.X95539.550000-233.835940
-0.24%
Bitcoin cryptocurrency
TSLA354.11-1.73
-0.49%
Tesla

BEAM and

Correlation & Price change

A.I.dvisor indicates that over the last year, BEAM has been closely correlated with CRSP. These tickers have moved in lockstep 71% of the time. This A.I.-generated data suggests there is a high statistical probability that if BEAM jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BEAM
1D Price
Change %
BEAM100%
+3.36%
CRSP - BEAM
71%
Closely correlated
+5.03%
NTLA - BEAM
62%
Loosely correlated
+7.76%
DNLI - BEAM
58%
Loosely correlated
+1.97%
PRME - BEAM
58%
Loosely correlated
+5.28%
RXRX - BEAM
57%
Loosely correlated
+1.04%
More

PRME and

Correlation & Price change

A.I.dvisor indicates that over the last year, PRME has been loosely correlated with CRSP. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if PRME jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PRME
1D Price
Change %
PRME100%
+5.28%
CRSP - PRME
64%
Loosely correlated
+5.03%
BEAM - PRME
59%
Loosely correlated
+3.36%
NTLA - PRME
57%
Loosely correlated
+7.76%
ALLO - PRME
54%
Loosely correlated
+39.22%
RXRX - PRME
53%
Loosely correlated
+1.04%
More